Alterity Therapeutics (ATH) H2 2025 earnings summary

Executive summary

• Achieved significant clinical milestones with lead asset ATH434, including completion of two Phase 2 trials in Multiple System Atrophy (MSA) showing statistically significant reduction in disease progression and favorable safety profile.

• ATH434 received Fast Track designation from the FDA and Orphan Drug status in both the US and EU, highlighting its potential as a first-in-class, disease-modifying therapy for MSA.

• Secured substantial additional funding of A$39.7 million, strengthening the cash position to A$33.2 million as of June 30, 2025.

• Developed innovative biomarker tools, such as the MSA Atrophy Index, enhancing diagnostic precision and clinical trial design.

Financial highlights

• Revenue from ordinary activities increased 66.3% year-over-year to A$446,291, primarily from interest income.

• Net loss after tax narrowed by 36.5% to A$12,147,828 compared to the prior year.

• Net tangible assets per share rose to 0.46 cents from 0.27 cents year-over-year.

• Cash and cash equivalents at year-end were A$33,158,642, up from A$12,638,885 the previous year.

• Research and development expenses decreased 22.7% to A$14,404,282, reflecting the completion of key studies.

Outlook and guidance

• Focus remains on advancing ATH434 through late-stage clinical development for MSA and expanding the pipeline into related neurodegenerative disorders.

• The company expects to continue incurring losses as it invests in R&D and clinical trials, with sufficient funding for at least the next 12 months.

• Additional external funding will be required for future development and commercialization efforts.